Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/nrc3930

http://scihub22266oqcxt.onion/10.1038/nrc3930
suck pdf from google scholar
C4491443!4491443 !25998715
unlimited free pdf from europmc25998715
    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25998715 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
pmid25998715
      Nat+Rev+Cancer 2015 ; 15 (6 ): 361-70
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Building better monoclonal antibody-based therapeutics #MMPMID25998715
  • Weiner GJ
  • Nat Rev Cancer 2015[Jun]; 15 (6 ): 361-70 PMID25998715 show ga
  • For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer therapy, but there is still much room for improvement. Efforts continue to build better cancer therapeutics based on mAbs. Anticancer mAbs function through various mechanisms, including directly targeting the malignant cells, modifying the host response, delivering cytotoxic moieties and retargeting cellular immunity towards the malignant cells. Characteristics of mAbs that affect their efficacy include antigen specificity, overall structure, affinity for the target antigen and how a mAb component is incorporated into a construct that can trigger target cell death. This Review discusses the various approaches to using mAb-based therapeutics to treat cancer and the strategies used to take advantage of the unique potential of each approach, and provides examples of current mAb-based treatments.
  • |Animals [MESH]
  • |Antibodies, Bispecific/pharmacology [MESH]
  • |Antibodies, Monoclonal/*chemistry/metabolism/*pharmacology [MESH]
  • |Antineoplastic Agents/*pharmacology [MESH]
  • |Humans [MESH]
  • |Immunoconjugates/pharmacology [MESH]
  • |Molecular Targeted Therapy/methods [MESH]
  • |Neoplasms/*drug therapy/immunology/pathology [MESH]
  • |Neovascularization, Pathologic/drug therapy/immunology [MESH]
  • |Signal Transduction/drug effects [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box